Stereotaxis Publishes Positive Results from MAGiC Catheter Study

Stereotaxis, Inc. (NYSE:STXS) is one of the 10 Best Small Cap Robotics Stocks to Buy Now. On July 1, Stereotaxis, Inc. (NYSE:STXS) published initial clinical results from the MAGiC catheter study. The authors of the study have solid experience and expertise, having treated more than 6,500 robotic procedures with older versions of magnetic catheters.

The study used MAGiC to treat patients suffering from arrhythmia in all four chambers of the heart. The study concluded with record safety and efficacy for 67 patients, with acute efficacy recorded at 94%. Currently, patient enrollment is still ongoing with sustained efficacy rates.

Stereotaxis Publishes Positive Results from MAGiC Catheter Study

A medical technician using surgical robotics to perform minimally-invasive urologic surgery in an operating room.

“We are delighted to see the strong efficacy and safety profile of MAGiC published in a prestigious journal. This publication supports our ongoing launch of MAGiC across Europe. We appreciate the pioneering electrophysiologists at Copenhagen University Hospital Rigshospitalet and Vilnius University Hospital Santaros Klinikos who made this possible,” said David Fischel, Stereotaxis Chairman and CEO.

Stereotaxis, Inc. (NYSE:STXS) is an innovative surgical robot developer for minimally invasive endovascular intervention. The company provides innovative solutions to physicians used to treat 150,000 patients across the world to date.

While we acknowledge the potential of STXS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than STXS and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.